Dry Eye Care Portfolio
Dry Eye Disease
CommercialActive
Key Facts
About YD Bio
YD Bio is a diversified biotech company with a multi-platform strategy spanning diagnostics, therapeutics, and clinical trial services. Its core focus is on DNA methylation-based early cancer detection, developed in partnership with EG Biomed, and exosome-based regenerative therapies for ophthalmology, developed with 3D Global Biotech. The company is publicly listed on Nasdaq, leverages strategic partnerships for R&D and commercialization, and operates a revenue-generating clinical trial supply business that supports its development-stage pipeline.
View full company profileTherapeutic Areas
Other Dry Eye Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Elate Ocular® | Cambium Bio | Phase 3 |
| OT-301 | Ocumension Therapeutics | Phase 2 |
| Avarept® Ophthalmic suspension 0.3% | Senju Pharmaceutical | Approved |
| Dry Eye Studies | Oculus Research | Not Applicable (Service Provider) |
| MediPrint Lens (Dry Eye) | MediPrint Ophthalmics | Pre-clinical/Research |
| Tivanisiran | Sylentis | Phase 2/3 |
| A197 | Aramis Biosciences | Phase 2 |
| KM102 | Theratome Bio | Pre-clinical |
| iTEAR®100 Commercialization | Olympic Ophthalmics | Commercial |
| HydraD | EyeD Pharma | Pre-Clinical |
| ST-100 (Vezocolmitide) | Stuart Therapeutics | Phase 3 |
| BRM421 | BRIM Biotechnology | Phase 3 |